D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 167 Citations 122,616 1,009 World Ranking 214 National Ranking 143
Best Scientists D-index 170 Citations 131,811 1,405 World Ranking 604 National Ranking 402

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

His primary areas of study are Internal medicine, Crohn's disease, Gastroenterology, Inflammatory bowel disease and Surgery. Jean-Frederic Colombel studied Internal medicine and Placebo that intersect with Clinical endpoint. His Crohn's disease research incorporates elements of Severity of illness, Clinical trial, Intestinal mucosa and Microbiology.

His research investigates the connection with Gastroenterology and areas like Adverse effect which intersect with concerns in Golimumab. As a member of one scientific family, Jean-Frederic Colombel mostly works in the field of Inflammatory bowel disease, focusing on Immunology and, on occasion, Irritable bowel syndrome, Anti–Saccharomyces cerevisiae antibody and Genotype. His Surgery study also includes

  • Vedolizumab which is related to area like Induction chemotherapy,
  • Natalizumab most often made with reference to Certolizumab pegol.

His most cited work include:

  • Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease (4710 citations)
  • Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
  • Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Crohn's disease, Gastroenterology, Inflammatory bowel disease and Ulcerative colitis. His Surgery research extends to Internal medicine, which is thematically connected. His Crohn's disease study combines topics in areas such as Adverse effect, Clinical trial, Randomized controlled trial and Maintenance therapy.

He has researched Gastroenterology in several fields, including Pathology, Placebo, Azathioprine and C-reactive protein. His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Incidence, Epidemiology, Immunology and Intensive care medicine. His Ulcerative colitis study frequently draws connections between adjacent fields such as Colitis.

He most often published in these fields:

  • Internal medicine (58.71%)
  • Crohn's disease (38.14%)
  • Gastroenterology (36.34%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (58.71%)
  • Inflammatory bowel disease (30.04%)
  • Crohn's disease (38.14%)

In recent papers he was focusing on the following fields of study:

His main research concerns Internal medicine, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis and Gastroenterology. His Vedolizumab, Clinical trial, Adverse effect and Ustekinumab study in the realm of Internal medicine interacts with subjects such as In patient. The various areas that he examines in his Inflammatory bowel disease study include Epidemiology, Immunology, Coronavirus disease 2019 and Intensive care medicine.

His Crohn's disease research integrates issues from Odds ratio, Infliximab, Calprotectin and C-reactive protein. His Ulcerative colitis study combines topics from a wide range of disciplines, such as Adalimumab, Tofacitinib, Colitis and Confidence interval. He interconnects Post-hoc analysis, Placebo and Hazard ratio in the investigation of issues within Gastroenterology.

Between 2017 and 2021, his most popular works were:

  • Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. (211 citations)
  • Adherent-invasive Escherichia coli in inflammatory bowel disease (138 citations)
  • Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis (132 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

Jean-Frederic Colombel mainly focuses on Internal medicine, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease and Gastroenterology. His work in Internal medicine covers topics such as Placebo which are related to areas like Randomized controlled trial. His research integrates issues of Psoriatic arthritis, Epidemiology, Incidence and Immunology in his study of Inflammatory bowel disease.

Jean-Frederic Colombel has researched Ulcerative colitis in several fields, including Clinical trial, Colitis, Retrospective cohort study, Intensive care medicine and Hazard ratio. His Crohn's disease research also works with subjects such as

  • C-reactive protein that connect with fields like Clinical endpoint,
  • Colonoscopy which is related to area like Endoscopy. He combines subjects such as Infliximab, Dysplasia, Meta-analysis, Primary sclerosing cholangitis and Pouchitis with his study of Gastroenterology.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

Jean-Pierre Hugot;Mathias Chamaillard;Mathias Chamaillard;Habib Zouali;Suzanne Lesage.
Nature (2001)

6358 Citations

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B Hanauer;Brian G Feagan;Gary R Lichtenstein;Lloyd F Mayer.
The Lancet (2002)

4780 Citations

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)

3902 Citations

Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

Mark S. Silverberg;Jack Satsangi;Tariq Ahmad;Ian D. R. Arnott.
Canadian Journal of Gastroenterology & Hepatology (2005)

3579 Citations

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean Frédéric Colombel;William J. Sandborn;Walter Reinisch;Gerassimos J. Mantzaris.
The New England Journal of Medicine (2010)

2973 Citations

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Jean–Frédéric Colombel;William J. Sandborn;Paul Rutgeerts;Robert Enns.
Gastroenterology (2007)

2350 Citations

Vedolizumab as induction and maintenance therapy for ulcerative colitis.

Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)

1794 Citations

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease

Arlette Darfeuille-Michaud;Jérôme Boudeau;Philippe Bulois;Christel Neut.
Gastroenterology (2004)

1765 Citations

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer.
The New England Journal of Medicine (2013)

1648 Citations

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

A. Dignass;G. Van Assche;J.O. Lindsay;M. Lémann.
Journal of Crohns & Colitis (2010)

1616 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jean-Frederic Colombel

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 488

Severine Vermeire

Severine Vermeire

KU Leuven

Publications: 427

William J. Sandborn

William J. Sandborn

University of California, San Diego

Publications: 415

Silvio Danese

Silvio Danese

Humanitas University

Publications: 306

Brian G. Feagan

Brian G. Feagan

University of Western Ontario

Publications: 274

Paul Rutgeerts

Paul Rutgeerts

KU Leuven

Publications: 265

Stefan Schreiber

Stefan Schreiber

Kiel University

Publications: 251

Gerhard Rogler

Gerhard Rogler

University of Zurich

Publications: 242

Peter L. Lakatos

Peter L. Lakatos

McGill University

Publications: 237

Javier P. Gisbert

Javier P. Gisbert

Autonomous University of Madrid

Publications: 228

Subrata Ghosh

Subrata Ghosh

University College Cork

Publications: 183

Edward V. Loftus

Edward V. Loftus

Mayo Clinic

Publications: 181

Gert Van Assche

Gert Van Assche

KU Leuven

Publications: 181

Stephen B. Hanauer

Stephen B. Hanauer

Northwestern University

Publications: 178

Marla Dubinsky

Marla Dubinsky

Icahn School of Medicine at Mount Sinai

Publications: 177

Jack Satsangi

Jack Satsangi

John Radcliffe Hospital

Publications: 175

Trending Scientists

Robert P. W. Duin

Robert P. W. Duin

Delft University of Technology

Marc Roper

Marc Roper

University of Strathclyde

Edward E. Leamer

Edward E. Leamer

University of California, Los Angeles

David E. Boyce

David E. Boyce

Northwestern University

Iiro Harjunkoski

Iiro Harjunkoski

Aalto University

Wenqing Zhang

Wenqing Zhang

Southern University of Science and Technology

Xiao-Yu Yang

Xiao-Yu Yang

Wuhan University of Technology

Mian Wu

Mian Wu

University of Science and Technology of China

Daniel F. Klessig

Daniel F. Klessig

Boyce Thompson Institute

Karsten Weis

Karsten Weis

ETH Zurich

Kai Bischof

Kai Bischof

University of Bremen

David L. Mitchell

David L. Mitchell

University of California, Berkeley

Takahiro Takano

Takahiro Takano

University of Rochester

Michael McCloskey

Michael McCloskey

Temple University

Russell C. Dale

Russell C. Dale

Children's Hospital at Westmead

Victor Asal

Victor Asal

University at Albany, State University of New York

Something went wrong. Please try again later.